[Hyper-thermo chemotherapy of esophageal cancer with thermosensitive liposome, TAC-1043]

Gan To Kagaku Ryoho. 1991 Aug;18(11):1760-3.
[Article in Japanese]

Abstract

Antitumor activity of the thermosensitive liposome, TAC-1043, was examined. The TAC-1043, produced by Takeda Chemical Industries, Ltd., contained entrapped cisplatin in a large unilamellar vesicle (LUV). LUV is composed of dipalmitoylphosphatidyl choline (DPPC) and distearoylphosphatidyl choline (DSPC) in the ratio of 9:1. The in vitro sensitivity of TAC-1043 was examined by SDI assay with MTT, using human esophageal cancer cell lines (TE-2, KY). TAC-1043 was effective at the concentration of 10 micrograms/ml, 41 degrees C and 43 degrees C. The in vivo effect of TAC-1043 together with hyperthermia was examined using mouse tumor MM 48. TAC-1043 combined with hyperthermia significantly suppressed the tumor proliferation.

MeSH terms

  • 1,2-Dipalmitoylphosphatidylcholine / administration & dosage
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Drug Carriers
  • Drug Screening Assays, Antitumor
  • Esophageal Neoplasms / pathology
  • Esophageal Neoplasms / therapy*
  • Hot Temperature / therapeutic use*
  • Humans
  • Liposomes
  • Mammary Neoplasms, Experimental / pathology
  • Mammary Neoplasms, Experimental / therapy
  • Mice
  • Phosphatidylcholines / administration & dosage
  • Tumor Cells, Cultured

Substances

  • Drug Carriers
  • Liposomes
  • Phosphatidylcholines
  • 1,2-Dipalmitoylphosphatidylcholine
  • 1,2-distearoyllecithin
  • Cisplatin